{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=43",
    "query": {
      "condition": "Recurrent Gliomas",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 1033,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T12:12:12.788Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00769093",
      "title": "Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Neoplasms"
      ],
      "interventions": [
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2008-10",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00769093"
    },
    {
      "nct_id": "NCT02271711",
      "title": "Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Ependymoma",
        "Recurrent Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Natural Killer Cell Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 12,
      "start_date": "2015-03-17",
      "completion_date": "2020-08-28",
      "has_results": false,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02271711"
    },
    {
      "nct_id": "NCT00025675",
      "title": "Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 105,
      "start_date": "2001-10-09",
      "completion_date": "2010-01-02",
      "has_results": false,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025675"
    },
    {
      "nct_id": "NCT00023634",
      "title": "S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumors",
        "Gastric Cancer",
        "Ovarian Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "KLH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GMCSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 14,
      "start_date": "2001-06",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 13,
      "location_summary": "Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more",
      "locations": [
        {
          "city": "Bay City",
          "state": "Michigan"
        },
        {
          "city": "Port Huron",
          "state": "Michigan"
        },
        {
          "city": "Bellingham",
          "state": "Washington"
        },
        {
          "city": "Bremerton",
          "state": "Washington"
        },
        {
          "city": "Mount Vernon",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023634"
    },
    {
      "nct_id": "NCT00597493",
      "title": "Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Sorafenib and Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00597493"
    },
    {
      "nct_id": "NCT04334863",
      "title": "WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumor",
        "Medulloblastoma",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "WP1066",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "3 Years to 25 Years"
      },
      "enrollment_count": 10,
      "start_date": "2020-05-04",
      "completion_date": "2023-02-03",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04334863"
    },
    {
      "nct_id": "NCT03245151",
      "title": "Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent and Refractory Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 64,
      "start_date": "2017-11-16",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03245151"
    },
    {
      "nct_id": "NCT00595322",
      "title": "Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Cancer",
        "Recurrent Malignant Gliomas",
        "Primary Brain Tumor"
      ],
      "interventions": [
        {
          "name": "bevacizumab and radiation (IMRT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2005-12",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2017-05-23",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 2,
      "location_summary": "Commack, New York • New York, New York",
      "locations": [
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00595322"
    },
    {
      "nct_id": "NCT00892177",
      "title": "Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dasatinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2009-10",
      "completion_date": "2019-07-01",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 305,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Pismo Beach, California + 179 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00892177"
    },
    {
      "nct_id": "NCT03727841",
      "title": "Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Ependymoma",
        "Ependymoma",
        "Ependymomas"
      ],
      "interventions": [
        {
          "name": "Marizomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4,
      "start_date": "2020-01-22",
      "completion_date": "2021-04-30",
      "has_results": true,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-10-23T12:12:12.788Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03727841"
    }
  ]
}